Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date |
Reported DateTime |
Company | Symbol | Insider Relationship |
Shares Traded |
Average Price |
Total Amount |
Shares Owned |
Filing |
| 2021-10-26 Purchase |
2021-10-26 5:04 pm |
Xilio Therapeutics Inc. | XLO | Rock Springs Capital Management LP Rock Springs Capital LLC Rock Springs Capital Master Fund LP Four Pines Master Fund LP 10% Owner |
500,000 | $16 | $8,000,000 | 1,256,472 (Indirect) |
View |
| 2021-10-26 Purchase |
2021-10-26 5:02 pm |
Xilio Therapeutics Inc. | XLO | BAY CITY CAPITAL LLC 10% Owner |
312,500 | $16 | $5,000,000 | 1,129,490 (Indirect) |
View |
| 2021-10-26 Purchase |
2021-10-26 5:01 pm |
Xilio Therapeutics Inc. | XLO | Atlas Venture Fund XI L.P. Atlas Venture Opportunity Fund I L.P. 10% Owner |
187,500 | $16 | $3,000,000 | 735,942 (Indirect) |
View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date |
Reported DateTime |
Exercisable Expiration |
Company | Symnbol | Insider Relationship |
Shares Traded |
Conversion Price |
Shares Owned |
Filing |
| 2021-10-26 Conversion |
2021-10-26 5:04 pm |
N/A N/A |
Xilio Therapeutics Inc. | XLO | Rock Springs Capital Management LP Rock Springs Capital LLC Rock Springs Capital Master Fund LP Four Pines Master Fund LP 10% Owner |
9,531,553 | $0 | 1,256,472 (Indirect) |
View |
| 2021-10-26 Conversion |
2021-10-26 5:02 pm |
N/A N/A |
Xilio Therapeutics Inc. | XLO | BAY CITY CAPITAL LLC 10% Owner |
8,578,397 | $0 | 1,129,490 (Indirect) |
View |
| 2021-10-26 Conversion |
2021-10-26 5:01 pm |
N/A N/A |
Xilio Therapeutics Inc. | XLO | Atlas Venture Fund XI L.P. Atlas Venture Opportunity Fund I L.P. 10% Owner |
26,728,062 | $0 | 735,942 (Indirect) |
View |
| 2021-10-26 Option Award |
2021-10-26 5:01 pm |
N/A 2030-07-22 |
Xilio Therapeutics Inc. | XLO | Clancy Paul J Director |
109,561 | $0 | 109,561 (Direct) |
View |
| 2021-10-26 Conversion |
2021-10-26 4:51 pm |
N/A N/A |
Xilio Therapeutics Inc. | XLO | Alexandria Venture Investments LLC 10% Owner |
1,747,449 | $0 | 166,423 (Direct) |
View |
| 2021-10-21 Option Award |
2021-10-25 5:18 pm |
N/A 2031-10-20 |
Xilio Therapeutics Inc. | XLO | Russo Rene CEO and President 10% Owner |
50,041 | $0 | 50,041 (Direct) |
View |
| 2021-10-21 Option Award |
2021-10-25 5:18 pm |
N/A 2031-10-20 |
Xilio Therapeutics Inc. | XLO | Ross Michael Jay Director |
26,400 | $0 | 26,400 (Direct) |
View |
| 2021-10-21 Option Award |
2021-10-25 5:17 pm |
N/A 2031-10-20 |
Xilio Therapeutics Inc. | XLO | Huber Martin H. Jr. President of R&D and CMO |
157,058 | $0 | 157,058 (Direct) |
View |
| 2021-10-21 Option Award |
2021-10-25 5:16 pm |
N/A 2031-10-20 |
Xilio Therapeutics Inc. | XLO | Giovine Salvatore Chief Financial Officer |
28,755 | $0 | 28,755 (Direct) |
View |
Ownership |
2021-10-22 8:16 pm |
N/A N/A |
Xilio Therapeutics Inc. | XLO | Williams John Charles 10% Owner |
0 | $0 | 100,080 (Direct) |
View |
Ownership |
2021-10-21 9:36 pm |
N/A N/A |
Xilio Therapeutics Inc. | XLO | Flynn James E Deerfield Mgmt L.P. DEERFIELD PARTNERS L.P. DEERFIELD MANAGEMENT COMPANY L.P. (SERIES C) Deerfield Mgmt V L.P. *Possible Member of 10% Group 10% Owner |
0 | $0 | 1,512,944 (Indirect) |
View |
Ownership |
2021-10-21 9:00 pm |
N/A N/A |
Xilio Therapeutics Inc. | XLO | FIL Ltd See Remark 1 10% Owner |
0 | $0 | 218,705 (Indirect) |
View |
Ownership |
2021-10-21 8:59 pm |
N/A N/A |
Xilio Therapeutics Inc. | XLO | Alexandria Venture Investments LLC 10% Owner |
0 | $0 | 166,423 (Direct) |
View |
Ownership |
2021-10-21 8:53 pm |
N/A N/A |
Xilio Therapeutics Inc. | XLO | Estate of Ulrich Rodeck 10% Owner |
0 | $0 | 100,080 (Direct) |
View |
Ownership |
2021-10-21 8:52 pm |
N/A N/A |
Xilio Therapeutics Inc. | XLO | CLACKSON TIMOTHY P 10% Owner |
0 | $0 | 111,751 (Direct) |
View |
Ownership |
2021-10-21 8:52 pm |
N/A N/A |
Xilio Therapeutics Inc. | XLO | TOMLINSON SIMON M 10% Owner |
0 | $0 | 131,117 (Direct) |
View |
Ownership |
2021-10-21 8:51 pm |
N/A N/A |
Xilio Therapeutics Inc. | XLO | Rock Springs Capital Management LP Rock Springs Capital LLC Rock Springs Capital Master Fund LP Four Pines Master Fund LP 10% Owner |
0 | $0 | 907,766 (Indirect) |
View |
Ownership |
2021-10-21 8:50 pm |
N/A N/A |
Xilio Therapeutics Inc. | XLO | Merck KGaA 10% Owner |
0 | $0 | 680,825 (Indirect) |
View |
Ownership |
2021-10-21 8:49 pm |
N/A N/A |
Xilio Therapeutics Inc. | XLO | BAY CITY CAPITAL LLC 10% Owner |
0 | $0 | 816,990 (Indirect) |
View |
Ownership |
2021-10-21 8:49 pm |
N/A N/A |
Xilio Therapeutics Inc. | XLO | FMR LLC See Remark 1 10% Owner |
0 | $0 | 1,907,670 (Indirect) |
View |
Ownership |
2021-10-21 8:48 pm |
N/A N/A |
Xilio Therapeutics Inc. | XLO | Atlas Venture Fund XI L.P. Atlas Venture Associates XI L.P. Atlas Venture Associates XI LLC Atlas Venture Opportunity Fund I L.P. Atlas Venture Associates Opportunity I L.P. Atlas Venture Associates Opportunity I LLC 10% Owner |
0 | $0 | 2,571,844 (Indirect) |
View |
Ownership |
2021-10-21 8:45 pm |
N/A N/A |
Xilio Therapeutics Inc. | XLO | Russo Rene CEO and President 10% Owner |
0 | $0 | 1,048,804 (Direct) |
View |
Ownership |
2021-10-21 8:45 pm |
N/A 2031-08-22 |
Xilio Therapeutics Inc. | XLO | Bonstein Sara Director |
0 | $0 | 53,213 (Direct) |
View |
Ownership |
2021-10-21 8:44 pm |
N/A 2031-03-28 |
Xilio Therapeutics Inc. | XLO | Giovine Salvatore Chief Financial Officer |
0 | $0 | 233,596 (Direct) |
View |
Ownership |
2021-10-21 8:44 pm |
N/A 2030-07-22 |
Xilio Therapeutics Inc. | XLO | Clancy Paul J Director |
0 | $0 | 58,134 (Direct) |
View |
Ownership |
2021-10-21 8:41 pm |
N/A N/A |
Xilio Therapeutics Inc. | XLO | HUMPHREY RACHEL Director |
0 | $0 | 58,133 (Direct) |
View |
Ownership |
2021-10-21 8:40 pm |
N/A N/A |
Xilio Therapeutics Inc. | XLO | RiverVest Venture Fund IV L.P. 10% Owner |
0 | $0 | 1,191,444 (Indirect) |
View |
Ownership |
2021-10-21 8:40 pm |
N/A N/A |
Xilio Therapeutics Inc. | XLO | TAKEDA PHARMACEUTICAL CO LTD Takeda Ventures Inc. 10% Owner |
0 | $0 | 1,475,121 (Indirect) |
View |
Ownership |
2021-10-21 8:40 pm |
N/A 2030-07-22 |
Xilio Therapeutics Inc. | XLO | Huber Martin H. Jr. President of R&D and CMO |
0 | $0 | 291,855 (Direct) |
View |
Ownership |
2021-10-21 8:40 pm |
N/A N/A |
Xilio Therapeutics Inc. | XLO | SV7 Impact Medicine Fund LP SV7 (IMF) GP LLP 10% Owner |
0 | $0 | 2,602,264 (Direct) |
View |
Ownership |
2021-10-21 8:39 pm |
N/A 2030-07-22 |
Xilio Therapeutics Inc. | XLO | LYNCH DANIEL Director 10% Owner |
0 | $0 | 335,394 (Direct) |
View |
Ownership |
2021-10-21 8:38 pm |
N/A 2031-06-16 |
Xilio Therapeutics Inc. | XLO | Rossi Christina Director |
0 | $0 | 53,213 (Direct) |
View |